The OM1 MS registry is a continually updating database of more than 20,000 patients prospectively followed with deep clinical, laboratory and other data, such as longitudinal outcomes, Expanded Disability Status Scale (EDSS) scores, relapses, subtypes, and treatment response. Additionally, researchers can tap into data from another 460,000 MS patients in the OM1 Real-World Data Cloud, which can be used for modelling, analytics, and other research purposes.
“The high availability and depth of the registry data enables healthcare stakeholders to answer important questions around natural history, disease progression, treatment response and outcomes. Early diagnosis and effective treatment are the best way to reduce the damaging effects and to improve an MS patient’s quality of life.”
— Dr. Richard Gliklich, CEO of OM1
[Source(s): OM1, PR Newswire]
Multiple Sclerosis and Occupational Therapy: How it Works
MedRhythms and Massachusetts General Hospital Launch Study of Gait Asset for Multiple Sclerosis
Pack Health Partners with National Multiple Sclerosis Society to Support Patients with MS